Why Did BEAT Stock Rocket 72% In Pre-Market Today?
Synopsis
The FDA has cleared HeartBeam’s 12-lead electrocardiogram synthesis software for arrhythmia assessment.
- The clearance enables HeartBeam’s cable-free technology to capture the heart’s electrical signals in three dimensions.
- The approval follows a successful appeal of a prior Not Substantially Equivalent (NSE) determination.
HeartBeam, Inc. (BEAT) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has cleared its 12-lead electrocardiogram (ECG) synthesis software for arrhythmia assessment, which enables its cable-free technology to capture the heart’s electrical signals in three dimensions and convert them into a complete 12-lead ECG.
The approval follows a successful appeal of a prior Not Substantially Equivalent (NSE) determination, marking a significant milestone for the company.
Why It Matters?
Unlike traditional single-lead or 6-lead devices, this innovation allows patients to obtain accurate cardiac readings from home, with synthesized results promptly reviewed by board-certified cardiologists.
Following the announcement, HeartBeam’s stock traded over 72% higher in Wednesday’s premarket.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.